Technology | June 08, 2015

GE Healthcare Launches Small Cyclotron and PET Tracer Production Solution

System enables increased access to PET imaging

GE Healthcare, FASTlab 2, FDG Duo, GENtrace cyclotron, PET imaging

FASTlab 2 with FDG Duo cassette image courtesy of GE Healthcare

June 8, 2015 - GE Healthcare announced that it has created a solution to make positron emission tomography (PET) tracers for diagnostic imaging more readily available. At the Society for Nuclear Medicine and Molecular Imaging (SNMMI), GE launched new products for radiopharmaceutical manufacturing, including GENtrace, a small cyclotron, with a smaller footprint that is optimized for ease-of-use; and FASTlab 2, a PET tracer production module with FDG Duo cassettes, to maximize the hot cell capacity.

Tracers for positron emission tomography (PET) imaging procedures play a critical role in medical care today. Yet the logistics of getting tracers onsite at healthcare providers' facilities can sometimes prove difficult for sites outside of radiopharmacies' distribution network, particularly in emerging markets.

The GENtrace cyclotron is the third instrument in GE's family of cyclotrons used to produce the isotope fluorine-18 (F-18), which provides the foundation for PET tracer manufacturing. The device is simple to use due to more automated steps, takes up less space and can be operated by a nuclear medicine technician. With these benefits, facilities in emerging markets and those outside the distribution radius for PET tracers can become autonomous in their F-18 manufacturing.

FASTlab 2 is the newest generation of the FASTlab platform for PET tracer production, which contains an automated cassette-based system and the assurance of reliable, reproducible and consistent quality during each run. Users are able to use two independent FASTlab 2 systems performing multiple runs in the same hot cell, gaining efficiency and saving time. FDG Duo is the new cassette complementing the existing FASTlab cassette portfolio, with integrated reagents allowing users to perform two consecutive fluorodeoxyglucose (FDG) citrate runs without having to open the hot cell door. Together, this allows up to four FDG runs or FDG runs with alternative PET tracers in combinations – maximizing the capacity and versatility of the instrument's hot cell output.

Like all other GE FASTlab cassettes, FDG Duo is a pre-assembled integrated cassette, with Good Manufacturing Process (GMP)-grade reagents included in the cassettes. FASTlab 2 also offers flexibility and range because it allows the use of tracer applications from third-party research partners and can help develop additional innovative tracers thanks to two built-in reactors. FASTlab 2 and FDG Duo cassettes can help customers optimize their PET tracer production and achieve more, providing flexible production capacity and better economics.

Using both the GENtrace cyclotron and FASTlab 2 automated PET tracer production platform as a package called TRACERcenter VIP, out-of-network facilities can provide increased access to PET tracers and benefit from the flexibility of customizing tracers for their specific patient needs.

For more information: www.gehealthcare.com

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Overlay Init